Pharmaceutical

AnGes files patent for crispr-based method for modifying mutant lRRK2 gene in cells

Discover how AnGes Inc. is revolutionizing Parkinson's disease treatment with RNA molecules and CRISPR technology. Learn about their patent for precise genetic modifications.

Mar 24, 2024 - 00:00
Discover how AnGes Inc. is revolutionizing Parkinson's disease treatment with RNA molecules and CRISPR technology. Learn about their patent for precise genetic modifications.
Read the original article

Tags:

Previous Article

Ascendis Pharma files patent for ocular drug delivery system using cross-linked Ha

Next Article

Ironwood Pharmaceuticals files patent for delayed release pharmaceutical composi...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novartis bags paediatric FDA label expansion for Lutathera

Novartis bags paediatric FDA label expansion for Lutathera

Apr 25, 2024

Expert analysis: the latest in HIV research and clinical trials 

Expert analysis: the latest in HIV research and clinica...

Jan 3, 2024

STAT+: Pharmalittle: FDA flags safety concerns with CRISPR-based sickle cell treatment; FDA warns about eye drop infection risk

STAT+: Pharmalittle: FDA flags safety concerns with CRI...

Oct 30, 2023